Navigation Links
China BCT Further Expands its Footprint by Opening 12 New Retail Pharmaceutical Stores
Date:7/28/2010

LIUZHOU CITY, GUANGXI PROVINCE, China, July 28 /PRNewswire-Asia-FirstCall/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that it has further expanded its retail network across Guangxi by opening 12 new retail pharmaceutical stores.

With an average size of 79.4 square meters, the new stores are located in highly populated and well attended locations, primarily in Liuzhou, Guilin, Nanning and Laibin cities. With a total expected capital investment of approximately $360,000, the average payback period of these stores is anticipated to be approximately 2.5 years. Management expects that these stores will generate approximately $2.2 million annually.

The stores will operate under the "Baicaotang" brand name and offer a diversified range of pharmaceutical products including nutraceuticals, cosmetics, Chinese herbal medicine and a limited number of the Company's private label pharmaceutical products. The Company has conducted comprehensive training to its staff in order to provide customers with accurate product information. So far, China BCT has attracted new recruits who possess professional knowledge related to the medical field.

Currently, the new stores are in their final stage of renovation and are expected to become fully operational by the end of July 2010. Management believes that the new stores will contribute approximately $930,000 to the Company's consolidated revenue in fiscal year 2010.

"In terms of retail footprint expansion, we deploy a two-pronged strategy which involves acquisitions and opening new stores," said Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT. "We believe this complementary approach is particularly effective. It enables us to establish our footprint in key locations by opening our own retail stores and allowing us to build upon existing sales of the stores we acquire by utilizing our renowned brand name."

About China BCT

China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries, Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited, each located in Guangxi province, China. The Company operates a large regional retail network in Guangxi province, consisting of 137 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit http://www.china-bct.com

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements related to anticipated revenue and payback period of the new stores. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward- looking information contained in this presentation.

    For more information, please contact:

    Company Contact:
     Ms. Shelly Zhang, Chief Financial Officer
     China BCT Pharmacy Group, Inc.
     Tel:     +86-772-363-8318
     Email:   shelly.zhang@china-bct.com
     Website: http://www.china-bct.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:     +1-646-213-1915
     Email:   crocker.coulson@ccgir.com

     Ms. Elaine Ketchmere
     VP of Financial Writing
     Tel:     +1-310-954-1345
     Email:   elaine.ketchmere@ccgir.com
     CCG Investor Relations
     Website: http://www.ccgirasia.com


'/>"/>
SOURCE China BCT Pharmacy Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , ... May 18, 2017 , ... When James Sherley, was notified earlier this year ... Valuable Brands for the Year 2017 by The Silicon Review , he was not ... good progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. ...
(Date:5/16/2017)... May 16, 2017 Telehealth has long ... and something that has been kept completely separate ... But according to   Logicalis Healthcare Solutions , ... IT solutions and managed services provider ( www.us.logicalis.com ... overlooked – interrelationship between telehealth, imaging, and EHR ...
(Date:5/15/2017)... ... 2017 , ... Algenist is continuing to disrupt the skincare ... with a patented formula, clinically proven to deliver visible firming results in 10 ... to our already innovative ELEVATE product line,” said vice president of product development ...
(Date:5/11/2017)... BOTHELL, Wash. , May 11, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife" or the "Company"), today reported operational highlights and ... Revenue from biopreservation media product sales reached a new high ... increase of 28% over the same period in 2016. Revenue ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):